I agree that there are many more possibilities to make this test a standard process. Everyone who gets an eye exam gets screened for glaucoma by that nasty machine that blows a puff of air in each eye and measures the pressure. The doctors don't generally own that machine and the test is not separately billable so they have to pay a fee for every test that they run to the distributor. I started with the two processes that I mentioned because we learned about them from Dr Rob's clinic's website. I think that suggests that this is how he is thinking of monetizing the test based on his approach to those procedures. I think that he can integrate this easily because it is a financial benefit for doctors rather than a liability like the glaucoma test.
Pretty steep upside potential from here if CLIA Waiver is approved.
The doctors on the AXIM EYE Board of Advisors are basically the All Star Team in this space.
These are not COVID-19 Tests where actual use was politicized.
These are Dry Eye Disease tests where there are very few current tests. Dry Eye Disease 510K tests that are already FDA approved and insurance reimbursable.
It seems like a very small step to receive a CLIA Waiver.
Market Data 
Markets 
AI
